PTOS825 (91-49)
Approved for use through 05/30/2005. 0/46 095-10-10-10
U.S. Palent and Trademark Office, U.S. DEPARTRENCY OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays availed 0/48 contrib curring.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING. DOCKEN Number (Optional)

REJECTION OVER A PENDING "REFERENCE" APPLICATION	DPP4-5004-C2
In re Application of: Jun Feng et al.	
Application No.: 10/809,637	
Filed: March 24, 2004	
FOI: DIPEPTIDYL PEPTIDASE INHIBITORS	
The owner", <u>TAMERA PRAMACEUTCAL COMPANY MATTED</u> of <u>1.00</u> , percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted to the instant application which would be eyed the expiration date of the full statutory term of any patent granted on pending reference Application Number <u>1.0080.635</u> .  The reference Application have the reference application which would be a set to term of a difference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent as granted on the instant application stant application stant application are commonly owned. This agreement runs with any patent granted on the instant application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statistory term as defined in 3 S U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent or the pending reference application," in the event that: any such patent; granted on the pending reference application, in the event that: any such patent; granted on the pending reference application; which even that are such patent; granted to the pending reference application; expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorly disclaimed in whole or terminally disclaimed under 3 CFR 1.32,1 has all claims canceled by a revenual reference application of its full statutory term as shortened by any terminal disclaimer flied prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
<ol> <li>For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.</li> </ol>	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and beller are believed to be true; and urther that these statements were made with the knowledge that willful rises statements the file so made are purishable by fire or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may loperardize the validity of the application or any patient issued thereon.	
2.  The undersigned is an attorney or agent of record. Reg. No. 38,394	
Mitchell R Buil	June 19, 2008
Signature	Date
Mitchell R. Brustein Typed or printed name	
	858-622-8528
	Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB96 may be used for making this statement. See MPEP § 324.	
This collection of information is required by 37 CFR 1.32! The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 5 US c. 12 cast 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or appearance of the complete of the process of the complete of the process of the complete of the complete of the use of the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or appearance of the use of	